Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
British Journal of Cancer
|
August 22, 2014
Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy
K S Courneya, D C McKenzie, J R Mackey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2021
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
G Curigliano, V Mueller, V Borges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 23, 2022
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]
G Curigliano, V Mueller, V Borges, et al.
Investigational New Drugs
|
February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
J Nehra, P A Bradbury, P M Ellis, et al.
British Journal of Cancer
|
July 29, 2010
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
S-J Dawson, N Makretsov, F M Blows, et al.
ESMO Open
|
June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
F Marmé, M Martin, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer
M R Jones, H Lim, Y Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2025
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B
S Loibl, M Martin, H Bonnefoi, et al.
Breast (Edinburgh, Scotland)
|
March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 15, 2023
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
S Loibl, F André, T Bachelot, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
British Journal of Cancer
|
August 22, 2014
Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy
K S Courneya, D C McKenzie, J R Mackey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2021
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
G Curigliano, V Mueller, V Borges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 23, 2022
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]
G Curigliano, V Mueller, V Borges, et al.
Investigational New Drugs
|
February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
J Nehra, P A Bradbury, P M Ellis, et al.
British Journal of Cancer
|
July 29, 2010
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
S-J Dawson, N Makretsov, F M Blows, et al.
ESMO Open
|
June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
F Marmé, M Martin, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer
M R Jones, H Lim, Y Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2025
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B
S Loibl, M Martin, H Bonnefoi, et al.
Breast (Edinburgh, Scotland)
|
March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 15, 2023
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
S Loibl, F André, T Bachelot, et al.
Page
of 6